1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Bristol Confident To Move Deucravacitinib Into Phase III Lupus Trial

 
• By Jessica Merrill

A Phase II study testing the TYK2 inhibitor in systemic lupus erythematosus met the primary endpoint. CMO Samit Hirawat talked to Scrip about the data and future development.

Lupus Ribbon
Bristol Myers is moving its TYK2 inhibitor into Phase III in lupus • Source: Shutterstock

Bristol Myers Squibb Company is hopeful that its oral tyrosine kinase 2 (TYK2) inhibitor deucravacitinib could offer a new potential mechanism of action to treat systemic lupus erythematosus (SLE), a challenging condition for drug development. The company announced on 1 June that a Phase II trial testing deucravacitinib in SLE met the primary endpoint and that it will advance the drug into Phase III testing in lupus by the end of the year.

The data are being presented as a late-breaking abstract at the European Alliance of Associations for Rheumatology (EULAR) Congress, and chief medical officer Samit Hirawat talked to

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

In Brief: Genmab To Seek FDA Nod For Epkinly In Lymphoma

 
• By Sushmita Panda

Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

More from R&D

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By Joseph Haas

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.